[This is an update, now with the video, of the original news post from the conference day, 20 October.]
It was a year ago, in September 2019, that H. Lundbeck announced its agreement to buy its industry colleague Alder in a deal valued at “up to” $2 billion. Both have a name in the area of brain diseases.
The setup included plans for bond issuance, a path that was eventually troubled by the covid-19 challenge.
“For setting the funding journey we had a bit of discussion with different consultancy firms but we decided to do this on our own,” says Markus Kede.